EUCTR2012-002273-54-AT进行中（未招募）不适用
A randomised, double-blind, placebo controlled, double dummy, four period crossover study to evaluate the efficacy, safety and tolerability of oral repeat doses of ONO-4053 and Cetirizine in subjects with seasonal allergic rhinitis in the Vienna Challenge Chamber.
Ono Pharmaceutical Co. Ltd.0 个研究点开始时间: 2012年10月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject has provided written informed consent, which signifies an agreement to enter the study and comply with the restrictions and requirements listed in the informed consent form.
- •2. The subject is aged between 18 and 65 years inclusive.
- •3. The subject has a body mass index of 19.0–30.0 kg/m2 inclusive and weighs =45.0 kg (female) and =50.0 kg (male) and no more than 100.0 kg at Screening (Visit 1).
- •4. The subject has a documented history of allergic rhinitis as determined by the presence of rhinitis symptoms that last for several months of the year, for at least two years, and are not attributed to infections or nasal abnormalities.
- •5. The subject has a positive skin prick test (wheal size = 3 mm) for grass pollen at Screening (Visit 1) or within the 12 months preceding Screening (Visit 1).
- •6. The subject has a serum specific IgE of at least 0.7kU/L (Radioallergosorbent test (RAST) = class 2) for grass pollen at Screening (Visit 1) or within the 12 months preceding Screening (Visit 1).
- •7. The subject exhibits a moderate to severe response to approximately 1500 grass pollen grains/m3 within the first 2 hours in the allergen challenge chamber at Screening (Visit 2). A moderate to severe response is defined as a total nasal symptom score of at least 6 (Total nasal symptom score is the sum of nasal obstruction, rhinorrhoea, itchy nose and sneezing, each of which has been scored on a scale from 0 to 3) and a nasal obstruction subscore of at least 2 (scored on a scale from 0 to 3).
- •8. The subject demonstrates a forced expiratory volume in one second (FEV1) = 80% of predicted (Standardized Lung Function Test per European Coal and Steel Community) at Screening (Visit 1 or 2).
- •9. Male subjects should be willing to use barrier contraception i.e., condoms with spermicide from the time of the first dose until 3 months after the last dose and agree to refrain from sperm donation for a period until 3 months after the last dose of study medication. Additionally, male subjects will be advised that their female partners of child-bearing potential should use an additional effective method of contraception for the same period.
- •10. Female subjects fulfil one of the following three criteria:
- •a) Post-menopausal, defined as amenorrhoea for at least 24 months together with an appropriate clinical profile (i.e., no alternative medical cause) and confirmed at Screening (Visit 1) by FSH levels above the lower limit of the laboratory range for post-menopausal women.
- •b) Not of child-bearing potential with a documented history of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
- •c) Of child-bearing potential with negative pregnancy test at Screening and on admission to the clinical unit (Visit 3), and must have a history of consistent use of a highly effective method of birth control for the previous 3 months of Screening (Visit 1) and be prepared to continue to use a highly effective method of contraception from Screening (Visit 1) until the Follow-up visit.
- •11. The subject is available to complete all study measurements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. The subject has a clinically relevant medical history, presence of any clinically significant disease or disorder, clinically significant laboratory, physical examination or ECG abnormalities at Screening (Visit 1 or 2) which in the opinion of the Investigator would place the subject at undue risk, influence the results or ability of the subject to participate in the study.
- •2. Pregnant or breast-feeding females.
- •3. The subject on examination is found to have nasal structural abnormalities or nasal polyps; nasal surgery = 56 days (8 weeks) prior to Screening (Visit 1).
- •4. The subject has a history of frequent nosebleeds, nasal biopsy, nasal trauma or nasal surgery.
- •5. The subject has a respiratory infection within 7 days, or a respiratory infection requiring antibiotic therapy within 14 days of Screening (Visits 1 and 2).
- •6. The subject has a respiratory disease, other than mild asthma not requiring treatment and associated with normal lung function.
- •7. The subject is concurrently participating, or has participated in a study with an investigational medicinal product during the previous 3 months or in any clinical study in the month prior to Screening (Visit 1).
- •8. The subject has used any medications within the time windows, which are stated in the table of section 8.1. Prohibited medication.
- •9. The subject regularly, or on average, drinks more than 3 units of alcohol per day - where 1 unit = ½ pint of beer (284mL), or 1 glass of wine (125mL), or 1 measure of spirit (25mL).
- •10. The subject is infected with Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) virus at Screening (Visit 1).
- •11. The subject has a current or chronic history of liver disease, or known hepatic (e.g. Gilbert’s syndrome) or biliary abnormalities.
- •12. The subject has an impaired hepatic function at Screening (Visit 1) defined as raised alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 x Upper limit of normal (ULN), alkaline phosphatase (ALP), total bilirubin or gamma glutamyl transpeptidase (GGT) >1.5 x ULN.
- •13. The subject has a history of an allergic drug or food reaction that, in the opinion of the responsible physician, contraindicates their participation (e.g. aspirin allergy, antibiotics allergy).
- •14. The subject has other clinically significant diseases or conditions which could interfere with the objectives of the study.
- •15. The subject has donated a unit of blood (=450mL) and/or received any blood or blood products within the previous 3 months of Screening (Visit 1) or intends to donate within 12 weeks of completing the study.
- •16. The subject has a positive test for drugs of abuse or alcohol at Screening (Visit 1).
- •17. The subject has a suspected hypersensitivity or intolerance to the study drugs or any ingredients of the study medication as detailed in the IB.
- •18. The subject has any conditions or factors which would make the subject unlikely to be able to stay in the chamber for 6 hours.
- •19. The subject is at risk of non-compliance with the study procedures/restrictions.
- •20. The subject has any other reason that the Investigator considers makes the subject unsuitable to participate.
研究者
相似试验
已完成
1 期
A study of aerosol Amikacin and Fosfomycin delivered via a new nebulizer system in mechanically ventilated patients.Ventilator Associated Pneumonia (VAP)Ventilator Associated Tracheobronchitis (VAT)Respiratory - Other respiratory disorders / diseasesACTRN12612000273886Cardeas Pharma9
已完成
不适用
A randomised, double-blind, placebo-controlled, dose-escalation study of multiple doses of BIIB014 administered orally in subjects with early Parkinson's diseaseParkinson's diseaseISRCTN55858075Biogen Idec Ltd (USA)40
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705B in COPD subjects.Study is in COPD patientsEUCTR2006-001419-30-BEGlaxoSmithKline Research and Development Ltd45
进行中（未招募）
1 期
A study of MEDI7352 in painful diabetic neuropathyPainful diabetic neuropathyMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002523-42-ESAstraZenecaAB271
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705B in COPD subjects.EUCTR2006-001419-30-SEGlaxoSmithKline Research and Development Ltd45